Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) FCF Margin: 2010-2025

Historic FCF Margin for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to 3.48%.

  • Heron Therapeutics' FCF Margin fell 548.00% to 3.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -20.08%, marking a year-over-year decrease of 1356.00%. This contributed to the annual value of -16.80% for FY2024, which is 3069.00% up from last year.
  • As of Q3 2025, Heron Therapeutics' FCF Margin stood at 3.48%, which was up 111.70% from -29.77% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' FCF Margin ranged from a high of 8.96% in Q3 2024 and a low of -282.08% during Q2 2021.
  • In the last 3 years, Heron Therapeutics' FCF Margin had a median value of -27.45% in 2024 and averaged -27.96%.
  • Per our database at Business Quant, Heron Therapeutics' FCF Margin plummeted by 7,220bps in 2021 and then surged by 17,822bps in 2022.
  • Heron Therapeutics' FCF Margin (Quarterly) stood at -221.00% in 2021, then surged by 9,463bps to -126.38% in 2022, then spiked by 13,282bps to 6.44% in 2023, then crashed by 3,689bps to -30.45% in 2024, then plummeted by 548bps to 3.48% in 2025.
  • Its FCF Margin was 3.48% in Q3 2025, compared to -29.77% in Q2 2025 and -23.08% in Q1 2025.